Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer (NCT03066297) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer
South Korea1,018 participantsStarted 2017-02-15
Plain-language summary
The investigatros hypothesized that selection of surgical procedure according to the pre-defined institutional decision-making algorithm will not compromise the treatment outcomes including overall survival and disease-free survival in participants with clinical stage IA non-small cell lung cancer.
The purpose of this study is to determine the outcome of participants with clinical stage IA NSCLC treated by 3 types of surgical resection (wide wedge resection, segmentectomy, or lobectomy) according to the institutional decision-making algorithm
The investigators are planning to enroll 1,000 participants who meet the pre-defined eligibility criteria over 5 years.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The following features should be fulfilled at preoperative thin-section CT scans
✓. Clinical stage T1a-bN0M0 (according to 7th AJCC staging system)
✓. Absence of proximal segmental or lobar bronchial involvement.
✓. NSCLC must be confirmed in intraoperative frozen section biopsies or postoperative pathologic examinations if the lesion was not histologically confirmed before operation.
✓. Age ≥ 18 years and \< 75 years.
✓. ECOG performance status 0-1.
✓. The patient should have adequate cardiopulmonary reserve to tolerate lobectomy (ppo FEV1 \> 40% and ppo DLCO \> 40% or VO2 max \> 15ml kg-1 min-1)
✓. No prior chemotherapy or thoracic radiotherapy for any malignancy.
Exclusion criteria
✕. Histologic diagnosis other than NSCLC (such as small cell lung cancer, carcinoid, pulmonary lymphoma, or other benign lung disease, etc).